Eric Ho

Eric Ho

bamobrien

Pharmacist turned technology executive, serial long in biotechnology, healthcare, and life sciences.

Recent articles

Insurance Ups and Downs for Diabetes Drugs in 2014

Managed care titans CVS Caremark and Express Scripts are undertaking major changes to their preferred drug formularies that may significantly impact a number of well-known diabetes medications and manufacturers.


Zogenix, Zohydro ER Face Familiar Post-Approval Hurdles

In a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...



Rite Aid, Walgreen, and CVS: Can In-Store Care Push Pharmacy Stocks Forward?

The tide has turned dramatically for in-store care clinics at major pharmacy retailers over the last few years. While previously growth for these services had stalled due to lack of dialogue between providers, new waves of partnerships for CVS, Walgreen, and Rite Aid are changing the game for convenient care.


The Weight Loss Drug Company Investors Need to Watch Out For

Big names like GlaxoSmithKline, Arena, VIVUS, and Orexigen are probably well-known among obesity market watchers, but this less publicized company out of Massachusetts is poised to change the landscape in coming years.

CVS Caremark's Big Thanksgiving Purchase: The Coram Buyout

The oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.




Eteplirsen in Question: Hope for Sarepta

Recent decisions by the Food and Drug Administration poses new questions about Sarepta Therapeutics, eteplirsen, and the future of DMD treatment.